Crossmark

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space

Crossref DOI link: https://doi.org/10.1208/s12248-026-01249-4

Published Online: 2026-06-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Morrow, Thomas https://orcid.org/0009-0002-5657-4161
Jarvi, Nicole https://orcid.org/0000-0001-6146-0324
Halota, Madeline https://orcid.org/0000-0002-4791-2299
Sun, Cheng https://orcid.org/0009-0007-1867-2760
Kafle, Prapti https://orcid.org/0000-0003-4682-2897
King, Rachel https://orcid.org/0009-0000-7151-9705
Okoh, Grace https://orcid.org/0009-0002-5631-3578
Patel, Sanjaykumar https://orcid.org/0009-0006-2225-1005
Heimbach, Tycho https://orcid.org/0000-0003-1224-0629
License Information

Text and Data Mining valid from 2026-06-08

Version of Record valid from 2026-06-08
More Information

Article History

Received: 23 December 2025

Accepted: 20 April 2026

First Online: 8 June 2026

Declarations

:

: The authors are shareholders of Merck &Co., Inc., Rahway, NJ, USA and declare no conflict of interest.